Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Anti-Cancer Agents in Medicinal Chemistry 2020-Sep

Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Линкът е запазен в клипборда
Paul Awolade
Nosipho Cele
Oluwakemi Ebenezer
Nagaraju Kerru
Lalitha Gummidi
Liang Gu
Gabriella Palma
Mandeep Kaur
Parvesh Singh

Ключови думи

Резюме

Background: The persistence of breast cancer as the leading cause of mortality among women, coupled with drug resistance to tamoxifen, the standard endocrine therapy for the disease, exacts fixated attention. To this effect, molecular hybridisation offers an attractive route to drugs with improved bioactivity profile.

Objective: The primary goal of this study was to examine the potentials of 1H-1,2,3-triazole linked quinoline-isatin molecular hybrids as drug candidates against breast cancer and methicillin-resistant Staphylococcus aureus (MRSA) cells.

Methods: The quinoline-isatin hybrids were synthesised via click chemistry-mediated molecular hybridisation strategy. Anti-breast cancer activity was determined in 3-(4,5-dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using estrogen-responsive (ER+) MCF-7 and MDA-MB-231 (triple-negative breast cancer -TNBC) cells while antimicrobial efficacy was established via the broth dilution method. Also, the toxicity profile of potent compounds to non-cancerous cells was determined using human embryonic kidney cells (HEK293) and human red blood cells (hRBCs). In silico techniques were employed to predict the drug-like properties of potent compounds and understand their binding modes with estrogen receptor alpha (ERα).

Results: Compounds 7g-i exhibited the strongest cytotoxicity to MCF-7 cells with IC50 values of 23.54, 23.66, and 32.50 μM, respectively. Interestingly, compound 7h also emerged as the best drug candidate against MDA-MB-231 and MRSA cells with IC50 = 71.40 μM and MIC80 = 27.34 μM, respectively. Structure-activity relationship analysis revealed that quinoline-2-carbaldehyde and 5,7- disubstituted isatin moieties confer desirable potency. These compounds showed no significant cytotoxic or haemolytic effects on HEK293 or hRBCs in vitro at their active concentrations; hence, eliciting their selectivity for cancer cells. In silico studies also presented the drugability of potent compounds and the likely structural features interacting with amino acid residues at the ligand-binding domain of ERα.

Conclusion: These results suggest that the identified 1H-1,2,3-triazole-linked quinoline-isatin hybrids are viable chemotypes that can be adopted as templates for the development of new anti-breast cancer and anti-MRSA agents.

Keywords: Breast cancer; in silico.; isatin; methicillin-resistant Staphylococcus aureus; molecular hybridisation; quinoline.

Присъединете се към нашата
страница във facebook

Най-пълната база данни за лечебни билки, подкрепена от науката

  • Работи на 55 езика
  • Билкови лекове, подкрепени от науката
  • Разпознаване на билки по изображение
  • Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
  • Прочетете научни публикации, свързани с вашето търсене
  • Търсете лечебни билки по техните ефекти
  • Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания

Google Play badgeApp Store badge